| Current Price | $2.27 | Mkt Cap | $162.4M |
|---|---|---|---|
| Open | $2.15 | P/E Ratio | 0.00 |
| Prev. Close | $2.27 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.09 - $2.28 | Volume | 96,245 |
| 52-Wk Range | $1.55 - $5.64 | Avg. Daily Vol. | 188,311 |
The Company designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite, or cath lab.
| Current Price | $2.27 | Mkt Cap | $162.4M |
|---|---|---|---|
| Open | $2.15 | P/E Ratio | 0.00 |
| Prev. Close | $2.27 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.09 - $2.28 | Volume | 96,245 |
| 52-Wk Range | $1.55 - $5.64 | Avg. Daily Vol. | 188,311 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about STXS.
Recs
naysaySA
(70.31)
Submitted: 6/19/2020 2:43:17 PM :
Start Price:
$4.03
NYSE MKT:STXS Score:
+57.46
Picked by a long stream of SA authors. So, I rate it an underperform. Note, it is trading at o er $5 [er share today, but CAPS lists it at $3.17,,,? Glitchy.
Recs
rhaltunen
(< 20)
Submitted: 1/17/2014 9:16:28 PM :
Start Price:
$5.57
NYSE MKT:STXS Score:
-180.25
I purchased this stock in 8/2013 based on technical analysis only. I noticed the large price and volume spike at the end of July. I waited a little too long to buy but still have a nice 8% gain. This was more of a speculative purchase than anything.
Recs
efti
(49.62)
Submitted: 9/9/2010 7:33:48 AM :
Start Price:
$39.80
NYSE MKT:STXS Score:
-359.22
The data of the last comparative trial
"At the European Cardiology Society Annual Congress in Stockholm last week, the research team led by Dr. Tamas Szili-Torok from the Erasmus Medical Center in Rotterdam presented the first comparative trial in a prospective study of 64 consecutive VT patients, comparing Stereotaxis VT ablation to conventional, non-magnetic ablation. Acute success was achieved in 97% of the Stereotaxis VT ablation group versus 81% of the manual ablation group. Patients in the Stereotaxis VT group averaged 50% less x-ray exposure, and after a year, only 14% VT recurrence, versus a 50% recurrence rate among manual ablation patients. A remarkable 25% reduction in total procedure time was achieved in the Stereotaxis VT group compared to the manual group.
There were no major complications in the Stereotaxis VT group compared to one death in the non-Stereotaxis group, representing a 4% major complication rate.
"The use of Stereotaxis offers major advantages for the ablation of VT," said Dr. Szili-Torok. "We have adopted a 100% utilization rule for our Stereotaxis lab for cardiac arrhythmias due to the significant benefits for our patients as well as for us as operators."
are impressive. If it was done fair they should explode.
Find the members with the highest scoring picks in STXS.
epc53 (26.55) Score: +516.06
The Score Leader is the player with the highest score across all their picks in STXS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| nicvo | 94.34 | 2/2/2009 |
|
5Y | $25.50 | -91.20% | +406.71% | +497.91 | 0 Comment | |
| smithtz | 87.97 | 2/4/2009 |
|
NS | $28.30 | -92.07% | +391.79% | +483.86 | 0 Comment | |
| epc53 | 26.55 | 1/26/2009 |
|
NS | $25.60 | -91.23% | +389.20% | +480.43 | 0 Comment | |
| anticitradeshort | 26.83 | 4/20/2009 |
|
NS | $33.20 | -93.24% | +381.19% | +474.43 | 0 Comment | |
| Maribaza | 97.33 | 7/27/2010 |
|
5Y | $42.60 | -94.73% | +265.19% | +359.92 | 1 Comment | |
| BLOWKE | < 20 | 4/14/2008 |
|
3W | $61.10 | -96.33% | +217.78% | +314.11 | 0 Comment | |
| megatrade | 90.61 | 3/3/2008 |
|
3W | $40.80 | -94.50% | +219.06% | +313.55 | 0 Comment | |
| ahknaten74 | 94.15 | 3/24/2008 |
|
NS | $44.80 | -94.99% | +216.89% | +311.88 | 0 Comment | |
| dmclain2 | 20.46 | 3/26/2008 |
|
NS | $56.80 | -96.05% | +214.19% | +310.24 | 0 Comment | |
| Calcio725 | 33.06 | 3/24/2008 |
|
3W | $56.30 | -96.01% | +211.60% | +307.61 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
